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Abstract
Introduction: Impaired renal function and/or pre-existing atherosclerosis in the deceased donor
increase the risk of delayed graft function and impaired long-term renal function in kidney transplant
recipients.
Case presentation: We report delayed graft function occurring simultaneously in two kidney
transplant recipients, aged 57-years-old and 39-years-old, who received renal allografts from the
same deceased donor. The 62-year-old donor died of cardiac arrest during an asthmatic state. Renal-
allograft biopsies performed in both kidney recipients because of delayed graft function revealed
cholesterol-crystal embolism. An empiric statin therapy in addition to low-dose acetylsalicylic acid
was initiated. After 10 and 6 hemodialysis sessions every 48 hours, respectively, both renal allografts
started to function. Glomerular filtration rates at discharge were 26 ml/min/1.73m
2 and 23.9 ml/min/
1.73m
2, and remained stable in follow-up examinations. Possible donor and surgical procedure-
dependent causes for cholesterol-crystal embolism are discussed.
Conclusion: Cholesterol-crystal embolism should be considered as a cause for delayed graft
function and long-term impaired renal allograft function, especially in the older donor population.
Introduction
Due to organ shortage, the acceptance of older and
marginal donors has become necessary. Impaired renal
function and/or pre-existing atherosclerosis or prevalent
cardiovascular risk factors in the deceased donor increase
the risk for delayed graft function (DGF) and impaired
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report two kidney recipients with DGF and impaired long-
term renal function who received renal allografts from the
same donor. In both cases, renal transplant biopsies were
performed on day 13 post-transplant revealing choles-
terol-crystal embolism (CCE).
Case presentation
Two men, both end-stage renal disease (ESRD) patients,
aged 57 years and 39 years respectively, received renal
transplants from a deceased donor. Class I and class II
human-leukocyte-antigen (HLA) antibodies were positive
in one patient pre-transplant. However, the HLAs of the
renal allograft were different from the patient’s HLA
antibodies. In addition, there were two HLA mismatches
in each patient. DGF occurred in both patients, lasting for
14 and 21 days, respectively, necessitating 6 and 10
hemodialysis sessions. Once renal function recovered,
glomerular filtration rate (GFR) leveled off at 26 ml/min/
1.73 m
2 and 23.9 ml/min/1.73m
2 by discharge, and
remained stable at a reduced level in follow-up examina-
tions (Figure 1).
Both kidney recipients had arterial hypertension as
comorbidity. Underlying kidney diseases were Alport
syndrome and chronic glomerulonephritis. Both patients
had been on chronic, intermittent hemodialysis (CIHD),
for 7 and 8.5 years respectively, before the current kidney
transplantation. One patient had previously received a
deceased-donor renal allograft that had failed after 14
years, so he had resumed CIHD.
The kidney donor was a 62-year-old man with hypoxic
brain damage after cardiac arrest for 10 minutes during an
acute asthma attack. In addition, he had a history of
smoking and needed insulin therapy while in the intensive
care unit. Based on the donor’s entry laboratory data at the
intensive care unit,theestimated GFR(6-variable equation
[2]) was 42.4 ml/min/1.73 m
2. At the time of organ
recovery, the renal arteries of the donor were classified as
atherosclerotic.
After successful implantation of the renal allografts using
an arterial end-to-side anastomosis of the renal artery to
the external iliac artery, there was no primary renal-
allograft function in both kidney recipients. However,
postoperative Doppler ultrasound examinations repeti-
tively showed a homogeneous perfusion in both renal
allografts. Resistance indices were between 0.67 and 0.76
(within the normal range).
During transplantation, the warm kidney ischemia period
was 46 and 65 minutes, and cold kidney ischemia lasted
for 11 hours 40 minutes and 19 hours 6 minutes. Both
patients received quadruple immunosuppression consist-
ing of a calcineurin inhibitor, prednisone and mycophe-
nolate mofetil in addition to induction therapy with an
interleukin-2 receptor antagonist.
Within 48 hours after transplant surgery, a revision surgery
was necessary in one case due to a bleeding complication.
The patient received a total of 6 units of packed
erythrocytes and remained in a stable condition. The
other patient experienced a cytomegalovirus (CMV)
reactivation 18 days post-transplant that was successfully
treated with ganciclovir for 14 days followed by CMV
prophylaxis with valganciclovir. Arterial hypertension
worsened in both patients when immunosuppressive
therapy was begun. In both patients, repeat physical
examination did not reveal evidence of livedo racemosa or
purple toes, both indicators of systemic CCE.
Besides laboratory parameters indicative of DGF, other
laboratory parameters including C-reactive protein, lactate
dehydrogenase and leukocyte count were not found to be
elevated. Specifically, there was no increased eosinophil
count.
Renal-transplant biopsies performed in both patients on
day 13 (34 and 25 glomeruli, Figure 2), and in one patient
on day 48 post-transplant (22 glomeruli, Figure 3) ruled
out renal-allograft rejection. Moreover, there was no
detection of polyomavirus nephropathy or cytomegalo-
virus antigen in either renal transplant. Besides signs of
moderate tubular injury, the histology of the bioptic
specimen revealed CCE in arterioles of both renal
allografts. Both renal allografts showed moderate to severe
nephrosclerosis with narrowing of the arterioles. However,
there was only one scarred glomerulus in each biopsy.
Figure 1.
Renal allograft dysfunction (serum creatinine including the
1-year follow-up) following cholesterol-crystal embolism in
two kidney recipients from the same deceased donor.
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vessels with cholesterol crystals. The biopsies were
negative for peritubular C4d or glomerular C3 comple-
ment. No baseline renal-transplant biopsy was performed
before implantation. The one follow-up renal biopsy
showed a picture similar to the index biopsy, however,
cholesterol crystals were not detected anymore, and
nephrosclerosis was more pronounced.
Fluvastatin, a statin with a good safety profile [3] due to
metabolism via the liver cytochrome P450 2C9 isoen-
zyme, was started in both patients in an attempt to
improve endothelial function. To rule out adverse side
effects, creatinine kinase was checked regularly. An empiric
therapy with acetylsalicylic acid was introduced to
counteract the thrombogenic “foreign-body” reaction of
cholesterol crystals. Prednisone therapy was given as
immunosuppression, and a potential therapeutic role for
CCE has been proposed [4].
Discussion
DGF and impaired long-term allograft function were
found to be associated with histologically proven CCE in
two renal allograft recipients from the same deceased
donor. However, a postoperative bleeding complication
in one patient, a prolonged cold and warm ischemia
period, and overall allograft quality from a donor
fulfilling extended donor criteria may have led to the
occurrence of DGF even without CCE. CCE mechanisms
for renal allograft failure including microvascular and
segmental-artery ischemia may have synergistically
compounded with other prevalent risk factors for DGF
resulting in irreversible kidney injury as an explanation
for the reduced long-term renal-allograft function seen
in both recipients.
The importance of CCE for acute kidney injury in native
kidneys has recently been reviewed emphasizing the
paucity of symptoms except for renal dysfunction [5].
For CCE in renal transplant patients, the same mechan-
isms and risk factors apply as for the general population.
Following renal transplantation, CCE of recipient origin
may occur at any time after transplantation. In contrast,
CCE of donor origin may have occurred either before or
during kidney procurement. Cholesterol crystals emanate
from the donor’s atherosclerotic renal artery that is
clamped or from a crushed plaque. In the cases presented
here, the donor appears to be the source for CCE because
there were no signs of systemic CCE such as livedo
racemosa or hypereosinophilia in the recipients. Secondly,
both donor kidneys were affected to the same extent and at
the same time following renal transplantation. Pre-existing
atherosclerosis, resuscitation efforts, anticoagulation at the
Figure 2.
Renal allograft biopsy of patient 1 shows cholesterol crystals
(arrow) in arterioles and interlobular arteries of the renal
allograft (Periodic acid Schiff stain, 200×, 3µm). Cholesterol
clefts are surrounded by macrophages and lymphocytes.
Lumina of preglomerular vessels are occluded. Glomeruli are
regular. Tubules are characterized by pseudo-dilatation with
flattened epithelia with tiny brush border (proximal tubules)
and irregular vacuolization (distal tubules).
Figure 3.
Renal allograft biopsy of patient 2 shows cholesterol crystals
(arrow) in arterioles and interlobular arteries of a renal
allograft from the same deceased donor (Periodic acid Schiff
stain, 400×, 3µm). Cholesterol clefts are surrounded by
macrophages and lymphocytes. Lumina of preglomerular
vessels are occluded. Glomeruli are regular. Tubules are
characterized by pseudo-dilatation with flattened epithelia
with tiny brush border (proximal tubules) and irregular
vacuolization (distal tubules).
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kidney procurement may have promoted CCE in the
kidney donor. There was no indication of repetitive CCE in
the one follow-up renal-transplant biopsy.
In the few known cases of CCE to renal transplants,
the ratio of recipient versus donor origin of CCE may
approximate 3:1 [6]. However, donor-related CCE
occurring shortly before or during renal transplantation
may go undetected because biopsies of the allograft
before implantation or in early phases of DGF are not
regularly performed [7, 8]. Even if biopsies are per-
formed, the diagnosis of CCE may be missed by
nephropathologists as the cholesterol content may be
diminished due to processing of the bioptic specimen. As
outlined above, other reasons like surgical stress,
prolonged cold and warm ischemia periods as well as
surgery-related complications may have partly explained
DGF in the two kidney recipients. In addition, the renal
transplant biopsy proven CCE may have contributed to
the DGF in both kidney recipients. CCE may become
more prevalent as a differential diagnosis for DGF with
older and/or comorbid kidney donors. Moreover, CCE
may be one reason for impaired long-term renal allograft
function.
In the general population, a longitudinal observational
study of proven cases demonstrated that 87% had one or
more precipitating risk factors such as angiography.
Twenty-four to 33% of patients with renal cholesterol-
crystal embolism develop ESRD [9, 10]. In the kidneys,
cholesterol crystals lead to thrombosis and inflammation
due to foreign body reaction thereby altering renal
function [7]. Given the detrimental effect of CCE on
renal survival in the general population, preventive
measures in the donor such as cautious anticoagulation
should be taken into consideration. For secondary
prevention, statin therapy may mediate plaque stabiliza-
tion at the sites of origin of CCE. In addition, there is a
rationale for acetylsalicylic acid to attenuate platelet
activation via cyclooxygenase-dependent pathways, or,
alternatively, for steroid therapy as anti-inflammatory
treatment strategy [4, 11]. Currently, there are no results of
randomized clinical trials for the treatment of CCE.
Concerning CCE in the renal transplant population,
therapeutic recommendations depend on the source of
CCE (kidney recipient versus kidney donor) and largely
rely on expert opinion [12].
Conclusions
CCE should be considered as a cause for DGF and poor
long-term graft function. Registry studies and/or protocol
renal-transplant biopsies may further clarify the preva-
lence of cholesterol embolism and help investigate
treatment strategies. In addition, identification of donors
at risk and the prevention of CCE in the donor should be
the goal.
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